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Genome-wide proﬁlingAlternative splicing is a highly regulated processwhich generates transcriptome and proteome diversity through
the skipping or inclusion of exons within gene loci. Identiﬁcation of aberrant alternative splicing associated with
human diseases has become feasible with the development of new genomic technologies and powerful bioinfor-
matics. We have previously reported genome-wide gene alterations in the neocortex of a well-characterized
cohort of Alzheimer's disease (AD) patients and matched elderly controls using a commercial exon microarray
platform [1]. Here, we provide detailed description of analyses aimed at identifying differential alternative
splicing events associated with AD.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).SpeciﬁcationsOrganism/cell line/tissue Temporal cortex (BA22) from AD patients and
matched elderly controlsSex 5 male and 3 female in each group
Sequencer or array type Affymetrix GeneChip® Exon 1.0 ST Array
Data format Raw data: CEL ﬁles; normalized data: SOFT,
MINiML and TXT
Experimental factors Diagnosis (AD versus control); sex; age; post-
mortem interval (PMI)
Experimental features The samples processed in each batch were
matched for AD versus control, sex and PMI
Consent (1) Subjects who died with autopsy, consent
was given by next-of-kin; (2) ethics review
board approval was obtained from the
respective institutions for the use of human
postmortem tissues.Sample source location OPTIMA (Oxford Project to Investigate
Memory and Ageing), a longitudinal,
clinicopathologic study of aging and dementia
(http://www.medsci.ox.ac.uk/optima)Direct link to deposited data
Deposited data (at the exon-level): http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE37264.Research, Singapore General
llege Road, Singapore 169856.
an).
. This is an open access article underDeposited data (at the gene-level): http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE37263.Experimental design, materials and methods
Study population, clinical and neuropathological data
Frozen post-mortem tissues from the superior temporal gyrus
(Brodmann area, BA22) of eight community-based AD patients recruit-
ed into OPTIMA (Oxford Project to Investigate Memory and Ageing), as
well as eight age- and sex-matched controls, were thawed on ice and
dissected free of meninges, blood vessel and white matter for further
processing. Informed consent had been obtained from the subjects'
next-of-kin before collection of brain tissues. Ethics review board
approval was obtained in the respective institutions in Singapore and
the UK for the use of human post-mortem tissues. Under OPTIMA, all
subjects underwent clinical and neuropsychological assessments,
including the Cambridge Cognitive Examination [2]. Subjects were clin-
ically diagnosed with AD using the National Institute of Neurological
and Communicable Diseases and Stroke (NINCDS) criteria [3], followed
with pathological conﬁrmation using the Consortium to Establish a
Registry for AD (CERAD) criteria [4]. The age-matched controls did not
have clinical evidence of dementia (CAMCOG scores N80 at the last
assessment before death) and died from non-neurological causes.
Braak staging of AD-related neuropathological changes [5] was also
performed. Six out of eight AD subjects were staged at V/VI (with two
at III/IV), while only one control was stage III/IV with the rest at 0–II.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Histogram plot revealed a similar distribution pattern of probeset intensities in all
samples. Probeset intensity is on X-axis and the frequency of the probeset intensity is on
Y-axis. Each line represents a sample.
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Total RNA extraction of 25–50 mg aliquots of dissected tissue was
performed using TRIzol reagent (Invitrogen, Carlsbad, CA) according
to the manufacturer's instructions. Quality of extracted RNA was evalu-
ated by agarose gel electrophoresis. 1 μg total RNA from each sample
was then processed for ribosomal RNA (rRNA) depletion with a
RiboMinus Human/Mouse Transcriptome Isolation Kit (Invitrogen).
Removal of rRNA was conﬁrmed using a 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA), and cDNA was generated with a
GeneChip Whole Transcript (WT) cDNA Synthesis and Ampliﬁcation
Kit (Affymetrix, Santa Clara, CA). Subsequently, cDNA was fragmented
and end-labeled using a AffymetrixWT Sense Target Labeling Kit before
hybridization to Affymetrix GeneChip Human Exon 1.0 ST Arrays at
45 °C for 16 h, then washed and stained in a Fluidics Station 450 and
scanned by a GCS3000 Scanner (both from Affymetrix) to generate
cell intensity (CEL) ﬁles using the Affymetrix GCOS software. The
sample process was limited by 4 available wash modules of the ﬂuidic
station. We thus matched 4 samples for AD versus control, sex and
post-mortem interval (PMI) as far as possible in each run to minimize
batch effects (Table 1).
Data analysis and normalization
Affymetrix CEL ﬁles were imported into Partek Genomics Suite 6.6
software (Partek Inc, Saint Louis, MO). Core meta-probeset ﬁle (HuEx-
1_0-st-v2.r2.dt1.hg18.core.mps) was employed to include the most
reliable probesets (exons) derived from NCBI's Reference Sequence
Database (RefSeq). Probe summarization and probeset normalization
were performed using RobustMulti-chip Average (RMA), which includ-
ed RMA background correction, quantile normalization, log2 base trans-
formation, and median Polish probe set summarization. Exploratory
data analysis was done by plotting histogram for each sample with the
intensity of the probeset on X-axis and the frequency of the probeset
intensity on the Y-axis. Histogram plot revealed that all of the samples
have a similar distribution pattern, indicating no obvious outliers of
the data (Fig. 1). The dataset consisting of about 232,000 probesets
has been deposited in the Gene Expression Omnibus database (GEO)
under accession number GSE37264. Furthermore,we generated another
dataset which consists of about 17,000 transcript clusters by averaging
the expression of all probesets on the same gene locus for the corre-
sponding transcript clusters. The dataset is available in GEO under
accession number GSE37263. Genomewide proﬁling of altered gene ex-
pression in AD has been reported previously [1].
Alternative splicing data analysis
A Partek alternative splice analysis of variance (ANOVA) model was
used to identify transcript clusters (genes) with one or more probesets
(exons) which were signiﬁcantly different from others in expression
between AD and controls. To reduce the generation of false-positiveTable 1
Matched samples for array processing.
Batch Control sample Sex Age PMI AD samples Sex Age PMI
1 op1044_CNT M 85 16 op388_AD M 83 29
op1151_CNT M 77 20 op417_AD M 67 30
2 op1146_CNT M 87 30 op91_AD M 66 42
op9_CNT F 79 29 op80_AD F 88 30
3 op223_CNT M 66 47 op133_AD M 69 44
op1132_CNT F 81 47 op340_AD F 63 48
4 op1112_CNT M 78 63 op450_AD M 78 88
op346_CNT F 88 115 op107_AD F 67 107
Batch, hybridization run; age, age of death (in year); PMI (in hours).results which can be caused by non-expressed exons, probesets with a
log2 b 3.0 in all samples were excluded from further analysis except
for those found signiﬁcantly and differently expressed between the
groups (p b 0.05). Using false discovery rate (FDR) adjusted values
of p b 0.01, 487 genes were identiﬁed as candidates for differential al-
ternative splicing events. An ideal differential alternative splicing
event is presented as equal expression of most of the exons in a gene
locus while one or a few exons are differentially expressed between
groups. Thus, among these candidates, those which exhibited signiﬁ-
cant changes at the gene level (AD vs control, p b 0.05), or fold change
N1.25 were excluded, resulting in 177 candidates for subsequent
evaluation.
Interpreting the results of alternative splicing analysis can be the
most challenging aspect of exon array analyses. For mutually exclusive
exons, differential alternative splicing can readily be identiﬁed. Howev-
er, inmost cases, it is difﬁcult to detect or interpret subtle changes in the
relative proportions of different transcript variants between groups.
Thus, the 177 candidates were manually inspected in Partek's Gene
View which is incorporated with the University of California, Santa
Cruz (UCSC) genome browser to localize differentially expressed
probesets in the context of transcript variants. Among these candidates,
we further classiﬁed the differential alternative splicing events as:
(1) Yes, the differentially expressed probeset maps to a known alterna-
tive spliced exon, and the transcript variant can be easily be identiﬁed;
(2) Probably, a single or more than one adjacent probesets behave
similarly in mapping to an exon but do not correspond to any known
transcript variants in RefSeq; and (3) Unlikely, differentially expressed
probesets exhibited minor changes or high signal variance, or probeset
mapped to regions of overlapping transcript clusters. Among the 177
candidates, 77 were removed due to the low likelihood of alternative
splicing events. We identiﬁed 22 candidates (BEGAIN, BRWD1,
CAMK2B, CYB5R3, EDF1, ELMO1, EPS15, FEZ1, FYN, GNAL, HK1,
HPCAL1, KCNS3, KLC1, MAP4, NTRK2, PACSIN1, SCN4B, SIPA1L1, TKT,
TRIM9 and ZNF365) with strong evidence of differential alternative
splicing events, of which two representatives are depicted here in
gene view plot (Fig. 2). The remaining candidates with possible
Fig. 2. Gene view plot revealed differential alternative splicing events associated with AD in GNAL and MAP4. The Y-axis is a log2 scale intensity value. (A) GNAL transcript variant 5
(NM_001261444)was signiﬁcantly down-regulated in AD, whereas transcript variant 1 (NM_182978) exhibited no change or slight increase in AD. (B)MAP4 transcript variant 3
(NM_030885) was signiﬁcantly down-regulated in AD, whereas transcript variant 1 (NM_002375) was signiﬁcantly up-regulated.
292 M.K.P. Lai et al. / Genomics Data 2 (2014) 290–292differential alternative splicing events (78 genes) require further conﬁr-
mation of the existence of corresponding transcript variants. The sup-
plementary table of 100 candidates with differential alternative
splicing associated with AD is available in GEO under accession number
GSE37264.
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